Advertisement
U.S. markets close in 1 hour 35 minutes
  • S&P 500

    5,088.80
    +1.77 (+0.03%)
     
  • Dow 30

    39,107.77
    +38.66 (+0.10%)
     
  • Nasdaq

    16,005.33
    -36.29 (-0.23%)
     
  • Russell 2000

    2,022.85
    +9.02 (+0.45%)
     
  • Crude Oil

    76.82
    -1.79 (-2.28%)
     
  • Gold

    2,050.10
    +19.40 (+0.96%)
     
  • Silver

    23.02
    +0.24 (+1.04%)
     
  • EUR/USD

    1.0825
    -0.0002 (-0.02%)
     
  • 10-Yr Bond

    4.2500
    -0.0770 (-1.78%)
     
  • GBP/USD

    1.2674
    +0.0016 (+0.13%)
     
  • USD/JPY

    150.3930
    -0.1070 (-0.07%)
     
  • Bitcoin USD

    51,169.60
    -358.09 (-0.69%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,706.28
    +21.79 (+0.28%)
     
  • Nikkei 225

    39,098.68
    +836.48 (+2.19%)
     

Director/PDMR Shareholding

DXS INTERNATIONAL PLC

Notification of Director / PDMR Dealing

The Board of DXS International plc (the “Company”), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems has received notification and notified the market that on 4 December 2023 Mr Bob Sutcliffe purchased a total of 400,000 Ordinary Shares in the Company at a price of 2.5p per share on behalf of himself and others.

One of the other persons acquiring beneficial ownership of Ordinary Shares as a result of Mr Sutcliffe’s purchase is David Immelman, the DXS Chief Executive, who has acquired a beneficial interest in 40,000 Ordinary Shares. Following this transaction Mr Immelman, and persons connected to him, have an interest in DXS Ordinary Shares of 6,563,829 Ordinary Shares representing 10.25% of the issued share capital of the Company.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

David Immelman

2

Reason for the notification

a)

Position/status

Chief Executive

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

 

DXS INTERNATIONAL PLC

b)

LEI

 

2138001R1KEUWTXEVJ44

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

 

 

Description of the financial instrument, type of instrument

Ordinary Shares of 0.33p each

 

 

Identification code

ISIN GB00B2Q6HZ92

 

 

b)

Nature of the transaction

Issue of new shares

c)

 

 

 

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

2.5p

40,000

 

 

 

 

 

 

d)

 

 

 

 

 

Aggregated information

 

 

 

- Aggregated volume

 

 

 

- Price

 

 

 

e)

Date of the transaction

 

4 December 2023

f)

Place of the transaction

 

Aquis Stock Exchange

The Directors of DXS International plc accept responsibility for this announcement.

Enquiries:

David Immelman      (Chief Executive)
DXS International plc

01252 719800
david@dxs-systems.com

Wrecclesham House
Wrecclesham Road
Farnham
Surrey
GU10 4PS

 

www.dxs-systems.co.uk

 


Corporate Advisor

 

David Papworth
City & Merchant

0207 101 7676


Corporate Broker

 

Hybridan LLP
Claire Louise Noyce

020 3764 2341

Note to Editors:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.


Advertisement